Lumenate Medical is developing a catheter-based cystoscope that lets non-urologist providers collect bladder images for remote review by board-certified urologists. Founded by a team that includes Johns Hopkins engineering and medical expertise, the Baltimore-based company is focused on shortening long waits for bladder cancer screening while keeping specialists in the decision-making loop. Its device remains in development and is not yet cleared or approved for sale by the U.S. Food and Drug Administration.
E&B Devices LLCE&B Devices is an early-stage medical device company. Their first product is a hands-free, no-prep screening device for colorectal cancer, and their pipeline includes devices for bladder cancer, fertility problems, and drug screening.
CareTech HumanDeveloped and launched in Ukraine, CareTech Human is a Cornell-supported health-technology company focused on making urological care more continuous and accessible. Its UroWell system helps urologists monitor patients remotely from the home, reducing reliance on frequent office visits and self-reported records. The company is currently piloting its approach with Weill Cornell Medical College.
Ultrasonic Medical Mapping, IncBethesda-based Ultrasonic Medical Mapping develops radiation-free cancer-detection technology, adapting a mature method from defense and aerospace testing for medical use. Its patented system is focused on finding pancreatic tumors earlier and at smaller sizes than existing imaging and non-imaging technologies, and the company has built a preclinical prototype for technical validation. UMM is now working toward clinical testing with hospital and clinical partners.BETHESDA, MD
ScreenHERFounded by Purdue-trained mechanical engineer and medtech commercialization leader Jennifer Estep, ScreenHER is a women’s health diagnostics company focused on making earlier cervical cancer detection more accessible. Its first platform application, UriCerve™, is being developed for rapid, non-invasive use at the point of care so clinicians can make decisions during the same visit. UriCerve™ remains under development and is not approved for clinical use.